FDA approves ResQCP� System for cardiac arrest-Advanced Circulatory Systems/Zoll

ZOLL Medical Corporation announced that the company�s ResQCPR� System has been granted premarket approval (PMA) by the FDA to market and begin U.S. distribution of the CPR adjunct system. The technology, which has been shown to improve the likelihood of survival in adult patients with non-traumatic cardiac arrest, is expected to be commercially available in mid-2015.

A pivotal study evaluating the ResQCPR System, known as the ResQTRIAL, which the FDA considered in its approval process, demonstrated a 49% increase in survival to one year in adult patients who experienced out-of-hospital cardiac arrest of presumed cardiac etiology, as compared to treatment with conventional manual CPR. If widely implemented, the ResQCPR System could save thousands of lives each year in the U.S. from out-of-hospital cardiac arrest alone, based on these study results.

The ResQCPR System uses Intrathoracic Pressure Regulation (IPR), a proprietary, non-invasive therapy developed by Advanced Circulatory Systems, Inc. of Roseville, Minn., which ZOLL acquired in January 2015. This innovative technology uses the body�s own mechanisms to enhance circulation without the use of pharmaceutical or other agents. The ResQCPR System is comprised of the ResQPOD� Impedance Threshold Device and the ResQPUMP� Active Compression-Decompression CPR Device, which work synergistically to improve perfusion.

Comment:The Centers for Disease Control and Prevention estimates that approximately 300,000 Americans experience an out-of-hospital cardiac arrest each year.